- Home
- VRCA vs ANIX Comparison
VRCA vs ANIX Comparison
Compare VRCA & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | ANIX |
|---|---|---|
| Founded | 2013 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 104.0M |
| IPO Year | 2018 | 2013 |
Fundamental Metrics
Financial Performance| Metric | VRCA | ANIX |
|---|---|---|
| Price | $5.53 | $2.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $17.00 | $9.00 |
| AVG Volume (30 Days) | ★ 108.5K | 82.4K |
| Earning Date | 03-11-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,577,000.00 | $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $103.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $0.39 | $2.33 |
| 52 Week High | $9.82 | $5.46 |
Technical Indicators
Market Signals| Indicator | VRCA | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 35.01 |
| Support Level | $5.18 | N/A |
| Resistance Level | $6.48 | $3.10 |
| Average True Range (ATR) | 0.53 | 0.17 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 26.60 | 2.22 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.